Skip to main content
Premium Trial:

Request an Annual Quote

Lipomics to Use Agilent Tools to Develop Assays for Metabolic Diseases

NEW YORK (GenomeWeb News) — Lipomics Technologies will use certain Agilent Technologies products under a research and diagnostic assay-development agreement, Lipomics said today.
 
Lipomics said it plans to develop biomarker-based assays focused on metabolic diseases caused by problems with lipid regulation.
 
Terms of the deal call for Agilent to contribute its 2100 Bioanalyzer and other products, including liquid and gas chromatographers, microarrays, and software as they are required, Lipomics said.
 
Lipomics said it measures more than 1,500 metabolites to generate profiles of lipid metabolism throughout the body.
 
Michael McNulty, general manager of Agilent’s diagnostics, life sciences, and chemical analysis business, said “both companies see significant synergies in combining” Lipomics’ experience with lipids and disease with Agilent’s “capabilities to separate, detect and analyze molecules. … ”
 
Financial terms of the agreement were not released.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.